A European Union Advocate General has recommended invalidating a portion of a directive that mandates pharmaceutical and cosmetics manufacturers to cover at least 80% of wastewater treatment expenses, marking a significant victory for the drug industry.
Originally revised and implemented early last year, the directive aimed to safeguard human health and the environment against hazardous urban wastewater discharges, ensuring cleaner waterways, lakes, groundwater, and coastlines throughout Europe. The initiative was projected to yield annual savings of approximately $7.5 billion by 2040.
STAT Plus: ‘Dump it down the drain’: How contaminants from prescription-drug factories pollute waterways
A central component of the directive involves a “quaternary treatment stage” dedicated to eliminating micropollutants—primarily generated by pharmaceutical and cosmetic production—from wastewater. Member states are required to guarantee corporate contributions to waste management programs by December 2028.